Clark Wealth Partners’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
Clark Wealth Partners's CRL Position: Q3 2026 in Review
Clark Wealth Partners increased its Charles River Laboratories (CRL) stake by 33% in Q3 2026, buying an estimated $264 and bringing the position to 4 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #782.
Clark Wealth Partners first reported a position in CRL in Q2 2025 and has held it in 6 quarters since. 642 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- Clark Wealth Partners held 4 shares of Charles River Laboratories worth $1.18K as of Q3 2026.
- Clark Wealth Partners bought 1 Charles River Laboratories share in Q3 2026, an estimated $264.
- Charles River Laboratories made up ﹤0.01% of Clark Wealth Partners's portfolio in Q3 2026, its #782 holding.
- Clark Wealth Partners first reported a position in Charles River Laboratories in Q2 2025 and has held it in 6 quarters since.
- 642 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on Clark Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.